Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 15/20 | 0.79 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.79 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213760 | 0.92 | PTGER4 (0.81) | PTGER4PTGER2PTGER3 | |
| SCHEMBL5213769 | 0.92 | PTGER4 (0.81) | PTGER4PTGER2PTGER3 | |
| SCHEMBL6616225 | 0.92 | PTGER4 (0.81) | PTGER4PTGER2PTGER3 | |
| SCHEMBL2446214 | 0.89 | PTGER4 (1.00) | PTGER4PTGER2PTGER3 | |
| SCHEMBL2446235 | 0.89 | PTGER4 (1.00) | PTGER4PTGER2PTGER3 | |
| SCHEMBL2446210 | 0.89 | PTGER4 (1.00) | PTGER4PTGER2PTGER3 | |
| SCHEMBL5183543 | 0.89 | PTGER4 (1.00) | PTGER4PTGER2PTGER3 | |
| SCHEMBL2447509 | 0.88 | PTGER4 (0.69) | PTGER4PTGER2PTGER3 | |
| SCHEMBL2447182 | 0.87 | PTGER4 (0.69) | PTGER4PTGER2PTGER3 | |
| SCHEMBL11666056 | 0.86 | PTGER4 (0.62) | PTGER4PTGER2PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | claimed |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | claimed |
| US-20050124577-A1 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | claimed |
| EP-1481976-B1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8026273-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7683094-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-7402605-B2 | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20050124577-A1 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| EP-1481976-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124577-A1 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | PTGER2, PTGIS, HPGDS | PTGER4 16/4885PTGER2 1/4885PTGER3 12/4885 |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | PTGER2, PTGIS, HPGDS | PTGER4 19/4885PTGER2 1/4885PTGER3 16/4885 |
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | PTGER2, PTGIS, HPGDS | PTGER4 19/4885PTGER2 1/4885PTGER3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.